Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 227

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 227
---
 but not limited to 
 clinical trial requirements for approvals;                                                                |

| • |     | legal disputes or other developments relating to proprietary rights, including patents, litigation matters and                                                                                                         
 New Semnur’s ability to obtain patent protection for its product candidate, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; |

| • |     | New Semnur’s decision to initiate a clinical trial, not initiate a clinical trial or to terminate an 
 existing clinical trial;                                                                             |

| • |     | New Semnur’s dependence on third parties; |

| • |     | announcements of the introduction of new products by New Semnur’s competitors; |

| • |     | market conditions and trends in the pharmaceutical and biotechnology sectors; |

| • |     | announcements concerning product development results or intellectual property rights of others; |

| • |     | future issuances of common stock or other securities; |

| • |     | the recruitment or departure of key personnel; |

| • |     | failure to meet or exceed any financial guidance or expectations regarding product development milestones that 
 New Semnur may provide to the public;                                                                          |

| • |     | actual or anticipated variations in quarterly operating results; |

| • |     | New Semnur’s failure to meet or exceed the estimates and projections of the investment community; |

131

| • |     | overall performance of the equity markets and other factors that may be unrelated to New Semnur’s operating               
 performance or the operating performance of its competitors, including changes in market valuations of similar companies; |

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by New 
 Semnur or its competitors;                                                                                      |

| • |     | changes in financial estimates by New Semnur or by any securities analysts who might cover its stock; |

| • |     | fluctuation of the market values of any of New Semnur’s potential strategic investments; |

| • |     | issuances of debt or equity securities; |

| • |     | compliance with New Semnur’s contractual obligations; |

| • |     | sales of New Semnur Common Stock by New Semnur or its stockholders in the future; |

| • |     | trading volume of New Semnur Common Stock; |

| • |     | ineffectiveness of New Semnur’s internal controls; |

| • |     | publication